Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Trainline shares surge on upbeat FY outlook as sales rise 8%

(Sharecast News) - Shares in Trainline surged on Thursday as the online ticketing platform said it expected full-year earnings to be at the upper end of guidance after an 8% jump in interim sales and would start a £150m share buyback. The company now expects adjusted core profits to grow at the top end of its previous guidance range of between 6% and 9%. Trainline shares were up 8% in London having risen 15% at one stage.

However, the stock is down 34% in the year to date after warnings about "headwinds", including the expansion of London's contactless travel zone and economic uncertainty denting foreign travel.

UK consumer net ticket sales for the six months to August 31 were 8% higher at £2.1bn, while the international business grew 2% to £594m as Trainline focused investment on European high-speed routes with emerging carrier competition.

In Southeast France, increased carrier competition between Paris, Lyon and Marseille drove second quarter sales growth of 34% driven by Trenitalia expanding its services in the region.

"Rail liberalisation in Europe continues to demonstrate the value Trainline brings as the preeminent domestic aggregator," said chief executive Jody Ford.

Analysts at broker Shore Capital retained their 'buy' recommendation on the stock, adding that they felt equity is being unfairly discounted due to "wider UK government noise", referring to plans to create a publicly-owned online train ticket retailer.

"Trainline is well positioned, in our view, to take advantage of the growing digitalisation of the UK rail network, explore European TAM opportunities in line with planned increased carrier competition, whilst also leveraging the proprietary technology platform for further customer engagement and B2B potential."

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.